Literature DB >> 15044083

Integrin-linked kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition.

Yoon-Ik Lee1, Yeon-Jin Kwon, Choun-Ki Joo.   

Abstract

The role of integrin-linked kinase (ILK) in transforming growth factor beta (TGFbeta)-mediated epithelial to mesenchymal transition was investigated. A stable transfection of dominant-negative ILK results in the prevention of TGFbeta-mediated E-cadherin delocalization. TGFbeta-mediated phosphorylation of Akt at Ser-473 was inhibited by dominant-negative ILK and PI3K inhibitors, LY294002 and wortmannin. Treatment with TGFbeta stimulated induction of Akt and ILK kinase activity in HaCat control cells. This increased ILK activity by TGFbeta was lowered by PI3K inhibitor, LY294002. In addition, PI3K inhibitor, dominant-negative Akt, and dominant-negative ILK could not block TGFbeta-mediated C-terminal phosphorylation of Smad2. Taken together, these data suggest that PI3K-ILK-Akt pathway that is independent of the TGFbeta-induced Smad pathway is required for TGFbeta-mediated epithelial to mesenchymal transition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044083     DOI: 10.1016/j.bbrc.2004.02.150

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Rik Derynck
Journal:  Cells Tissues Organs       Date:  2010-11-02       Impact factor: 2.481

Review 2.  Significance of talin in cancer progression and metastasis.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

3.  A critical role of serum response factor in myofibroblast differentiation during experimental oesophageal ulcer healing in rats.

Authors:  Jianyuan Chai; Manith Norng; Andrzej S Tarnawski; Justine Chow
Journal:  Gut       Date:  2006-10-26       Impact factor: 23.059

4.  ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance.

Authors:  Dimitrios Tsoumas; Sofia Nikou; Efstathia Giannopoulou; Spyridon Champeris Tsaniras; Chaido Sirinian; Ioannis Maroulis; Stavros Taraviras; Vassiliki Zolota; Haralabos P Kalofonos; Vasiliki Bravou
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

Review 5.  Mechanisms of the epithelial-mesenchymal transition by TGF-beta.

Authors:  Michael K Wendt; Tressa M Allington; William P Schiemann
Journal:  Future Oncol       Date:  2009-10       Impact factor: 3.404

6.  ILK-PI3K/AKT pathway participates in cutaneous wound contraction by regulating fibroblast migration and differentiation to myofibroblast.

Authors:  Gang Li; Ye-Yang Li; Jing-En Sun; Wei-Hua Lin; Ri-Xing Zhou
Journal:  Lab Invest       Date:  2016-04-25       Impact factor: 5.662

7.  Downregulation of lentivirus-mediated ILK RNAi on tractional force generation in human retinal Müller cells.

Authors:  Yu-ping Zheng; Hui Liu; Hao Zeng; Lei Xiong; Zhao-hui Feng; Nai-xue Sun
Journal:  Acta Pharmacol Sin       Date:  2009-11-16       Impact factor: 6.150

Review 8.  TGF-beta-induced epithelial to mesenchymal transition.

Authors:  Jian Xu; Samy Lamouille; Rik Derynck
Journal:  Cell Res       Date:  2009-02       Impact factor: 25.617

9.  TGFβ1-induced cell motility but not cell proliferation is mediated through Cten in colorectal cancer.

Authors:  Abdulaziz Asiri; Teresa Pereira Raposo; Abdulaziz Alfahed; Mohammad Ilyas
Journal:  Int J Exp Pathol       Date:  2019-01-15       Impact factor: 1.925

10.  Integrin alpha3beta1-dependent beta-catenin phosphorylation links epithelial Smad signaling to cell contacts.

Authors:  Young Kim; Matthias C Kugler; Ying Wei; Kevin K Kim; Xiaopeng Li; Alexis N Brumwell; Harold A Chapman
Journal:  J Cell Biol       Date:  2009-01-26       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.